BioSpace News Archive

Calidi Biotherapeutics, Inc. today announced an upcoming presentation at the 7th Annual Oncolytic Virotherapy Summit, taking place in Boston, Massachusetts and virtually, December 6-8, 2022.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively.

Vistagen today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of PH10, one of the Company’s investigational nasal sprays, for the treatment of major depressive disorder (MDD).

According to Nova one advisor, the global Age-related Macular Degeneration market size was estimated at USD 10.40 billion in 2022 and is projected to hit around USD 18.29 billion by 2030, growing at a CAGR of 6.70% during the forecast period 2022 to 2030.

According to Nova one advisor, the global AI In Cancer Diagnostics market size is expected to hit around USD 1.2 billion by 2030 from valued at USD 93.9 million in 2021 and growing at a CAGR of 28.9% from 2022 to 2030.

According to Nova one advisor, the global Drug Discovery Services market size is expected to hit around USD 34.2 billion by 2030 from valued at USD 16.9 billion in 2021 and growing at a CAGR of 14.9% from 2022 to 2030.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants.

Mainz Biomed NV announced that it has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.

ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.

Natera, Inc., a global leader in cell-free DNA testing, announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide polymorphism -based noninvasive prenatal test.